Abstract
Evaluation of the cytotoxic activity of Tamarix articulata and its anticancer potential in prostate cancer cells
Highlights
Tumor metastasis is a series of events governed by complex mechanisms that are initiated by the detachment of tumor cells, followed by invasion, migration, endothelial cell adhesion, and reestablishment of tumor growth at distantAlnuqaydan et al / Journal of Applied Pharmaceutical Science 12 (02); 2022: 089-108 clinically present with bone metastasis (Stavridi et al, 2010)
We proposed to examine the antiproliferative potential of Tamarix articulata (TA) extract on the cellular growth of prostate cancer (PC-3, DU 145, LnCaP, C42B, and VCaP) cells and normal benign prostate hyperplasia (BPH) cell line
Our results showed that a significant reduction of Brd U incorporation (*p < 0.05; **p < 0.01) (Fig. 1b) and viability of cells by trypan blue exclusion assay (*p < 0.05; **p < 0.01) (Fig. 1c) were observed after prostate cancer cells were exposed to varying doses of TA extract for 24 hours
Summary
Tumor metastasis is a series of events governed by complex mechanisms that are initiated by the detachment of tumor cells, followed by invasion, migration, endothelial cell adhesion, and reestablishment of tumor growth at distantAlnuqaydan et al / Journal of Applied Pharmaceutical Science 12 (02); 2022: 089-108 clinically present with bone metastasis (Stavridi et al, 2010). The therapeutic interventions for prostate cancer are surgery (radical prostatectomy), radiotherapy, and adjuvant chemotherapy (Suardi et al, 2014). The bone-associated metastasis in prostate cancer is extremely resistant to radiotherapy and to the present regiment of ablation of androgen therapy (Suardi et al, 2014). Owing to the development of androgen-independent prostate cancer, relapse is inevitable approximately after 18 months in prostate cancer metastasis. This indicates that there is no therapeutic option for metastatic prostate cancer patients thereafter (Zhang et al, 2017). For this reason, new therapeutics are urgently required to treat metastatic prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
